Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12580589 | 0.94 | — | — | |
| SCHEMBL24613024 | 0.85 | SMN1; SMN2 (0.57) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL21011845 | 0.83 | ALDH1A1 (0.49) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL13195715 | 0.81 | ALDH1A1 (0.58) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL14423917 | 0.80 | ALDH1A1 (0.57) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL15894023 | 0.80 | ALDH1A1 (0.57) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL14195457 | 0.79 | ALDH1A1 (0.59) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL9076343 | 0.78 | — | — | |
| SCHEMBL2618045 | 0.77 | ALDH1A1 (0.54) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL2513477 | 0.77 | ALDH1A1 (0.52) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023101556-A1 | NOVEL INHIBITORS OF ASPARTATE TRANSCARBAMOYLASE (ATCASE) AND COMPOSITIONS, METHODS AND USES RELATED THERETO. | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2023-06-08 | — | — | WO | disclosed |
| EP-2726459-B1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | BARUCH S BLUMBERG INST (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-2752401-B1 | PRODUCTION METHOD FOR 2-ALKENYLAMINE COMPOUND | SHOWA DENKO KK (JP) | 2018-10-10 | — | — | EP | disclosed |
| EP-2752402-B1 | PRODUCTION METHOD FOR 2-ALKENYLAMINE COMPOUND | SHOWA DENKO KK (JP) | 2018-06-27 | — | — | EP | disclosed |
| US-20170320818-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | UNIV DREXEL (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170266197-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS B VIRUS INFECTIONS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-09-21 | — | — | US | disclosed |
| US-9758477-B2 | Sulfamoylbenzamide derivatives as antiviral agents against HBV infection | DREXEL UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170204086-A1 | ALPHA-HELIX ANALOG HAVING TRIAZINE-PIPERAZINE BACKBONE AND METHOD FOR PREPARING SAME | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2017-07-20 | — | — | US | disclosed |
| US-9440907-B2 | Production method for 2-alkenylamine compound | SHOWA DENKO K.K. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-9399619-B2 | Sulfamoylbenzamide derivatives as antiviral agents against HBV infection | BARUCH S. BLUMBERG INSTITUTE (US) | 2016-07-26 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070149596-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| WO-2006074051-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION | DIAKINE THERAPEUTICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| US-6310095-B1 | INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE | UNIVERSITY OF PITTSBURGH | 2001-10-30 | — | — | US | disclosed |
| US-5332821-A | Process for preparing isoquinolines | HOFFMANN-LA ROCHE INC. (US) | 1994-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204086-A1 | ALPHA-HELIX ANALOG HAVING TRIAZINE-PIPERAZINE BACKBONE AND METHOD FOR PREPARING SAME | HSPH1, HBZ, PITHD1 | ALDH1A1 2784/4885ALOX15 4775/4885PKM 3224/4885 |
| US-20170320818-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | ALKBH5, SULT1A1, SHMT1 | ALDH1A1 2034/4885ALOX15 2653/4885PKM 862/4885 |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | ALDH1A1 904/4885ALOX15 3301/4885PKM 1562/4885 |
| US-20170266197-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS B VIRUS INFECTIONS | HAVCR2, HCCS, PYGL | ALDH1A1 1471/4885ALOX15 820/4885PKM 3760/4885 |
| US-20070149596-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | PYCR1, PRMT9, PRLHR | ALDH1A1 513/4885ALOX15 2933/4885PKM 721/4885 |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | CX3CR1, CCL5, CCRL2 | ALDH1A1 4356/4885ALOX15 2273/4885PKM 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.